A NOVEL LC-MS/MS TECHNIQUE FOR THE QUANTITATION OF LURBINECTEDIN IN HUMAN PLASMA: APPLICATION OF STABILITY STUDIES

PRATHYUSHA KOTHA; CHANDRASHEKARA RAO BARU; CHAMAKURI KANTLAM

doi:10.22159/ijap.2025v17i6.53642

Authors

PRATHYUSHA KOTHA Bharatiya Engineering Science and Technology Innovation University, Anantapur-515231, Andhra Pradesh, India
CHANDRASHEKARA RAO BARU Department of Pharmacy, Chilkur Balaji College of Pharmacy, Aziz Nagar, Moinabad Road-500075, Telangana, India
CHAMAKURI KANTLAM Faculty of Pharmacy, Brilliant Grammar School Educational Society’s Group of Institutions-Integrated Campus(Faculty of Engineering and Faculty of Pharmacy), Rangareddy, Hyderabad-501505, Telangana, India https://orcid.org/0000-0002-1630-9294

DOI:

https://doi.org/10.22159/ijap.2025v17i6.53642

Keywords:

Cancer, Lurbinectedin, LC-MS/MS, Validation, Accuracy

Abstract

Objective: A linear and precise liquid chromatography coupled with tandem mass spectrometry method was developed and validated for the quantification of lurbinectedin in plasma. Canagliflozin served as an internal standard (IS).

Methods: The plasma extraction utilized 5 ml of ethyl acetate as the solvent. The examination was performed utilizing a Zorbax ODS (50 mm × 2.1 mm x 3µ) stationary phase at ambient conditions, with a mobile phase comprising 0.1% HCOOH, acetonitrile, and methyl alcohol in a ratio of 15:50:35. The measurement of the mobile phase's flow rate was recorded at 0.4 ml/min. In positive ionization mode utilizing electrospray, the drug and internal standard were detected, resulting in mass transitions of (m/z): Lurbinectedin, 785.30/711.20 and Canagliflozin (IS), 445.15/267.12.

Results: A linear correlation was established between the concentrations of Lurbinectedin and their corresponding peak proportions to canagliflozin across the concentration range of 0.2-3200 ng/ml. The precision for Lurbinectedin, measured both within the same day and across different days, was determined to be ≤5.18%. Inter and intra-day bias ranged from −4.17% to 4.53. The measured average extraction recovery for Lurbinectedin was found to be 99.23%. The measurement of the internal standard's recovery was found to be 98.31%. Lurbinectedin was subjected to thorough assessment regarding its long-term, freeze-thaw, bench top, short-term stability, auto sampler, dry extract, and stock solution stability at both low quality control (QC) and high QC levels, showing consistent stability across all evaluated conditions.

Conclusion: The developed method has become a cornerstone of modern clinical laboratories due to its versatility, sensitivity, and precision, and its ability to support both routine clinical diagnostics and cutting-edge personalized medicine.

References

1. Wu YL, Smit EF, Bauer TM. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: a review of preclinical and clinical studies. Cancer Treat Rev. 2021;95:102173. doi: 10.1016/j.ctrv.2021.102173, PMID 33740553.

2. Esaki T, Hirai F, Makiyama A, Seto T, Bando H, Naito Y. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors. Cancer Sci. 2019;110(4):1340-51. doi: 10.1111/cas.13956, PMID 30724423.

3. Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM. Phase 1 study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts. Cancer Sci. 2020;111(2):536-47. doi: 10.1111/cas.14254, PMID 31778267.

4. Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, Huai Xiang Hao, Angela Tam, Hui Qin Wang, Jinsheng Liang, Matthew T DiMare, Hyo Eun Carrie Bhang, Youzhen Wang, Pascal Furet, William R Sellers, Francesco Hofmann, Joseph Schoepfer, Ralph Tiedt. Lurbinectedin (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clinical Cancer Research. 2019 May 15;25(10):3164–75. doi: 10.1158/1078-0432.CCR-18-2814.

5. Upadhya A, Yadav KS, Misra A. Targeted drug therapy in non-small cell lung cancer: clinical significance and possible solutions-part I. Expert Opin Drug Deliv. 2021;18(1):73-102. doi: 10.1080/17425247.2021.1825377, PMID 32954834.

6. Lolla S, Gubbiyappa KS. Development and validation of and LC-MS/MS method to quantify Capmatinib in human plasma: application to a pharmacokinetic study in rabbits. J Appl Pharm Sci. 2023;13:3. doi: 10.7324/JAPS.2023.131969.

7. Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM. A novel kinase inhibitor INCB28060, blocks c-MET-dependent signaling neoplastic activities and cross talk with EGFR and HER-3. Clin Cancer Res. 2011;17(22):7127-38. doi: 10.1158/1078-0432.CCR-11-1157, PMID 21918175.

8. Glaenzel U, Jin Y, Hansen R, Schroer K, Gholamreza Rahmanzadeh U Pfaar, Jan Jaap Van Lier, Hubert Borell, Axel Meissner, Gian Camenischand Sylvia Zhao. Absorption distribution metabolism and excretion of lurbinectedin (INC280) in healthy male volunteers and in vitro aldehyde oxidase phenotyping of the major metabolite. Drug Metabolism and Disposition. 2020;48(10):873-85. doi: 10.1124/dmd.119.090324.

9. U. S. Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville (MD): U. S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM); 2001 May.

10. Dadhaniya T, Chaudhary K, Mehta P. Development of LC-MS/MS method for determination of iloperidone in rabbit plasma: application to a pharmacokinetic study. Int J Pharm Pharm Sci. 2013;7(4):294-7.

11. Ponnuri RN, Pragallapati P, NR, Mandava VB. A rapid and sensitive liquid chromatography mass spectrometry/mass spectrometry method for estimation of pioglitazone keto pioglitazone and hydroxy pioglitazone in human plasma. Asian J Pharm Clin Res. 2017;10(12)120-8. doi: 10.22159/ajpcr.2017.v10i12.20284.

12. Sura RS, CVS S, Rachamalla SS. Bioanalytical RP-HPLC method development and validation of clopidogrel bisulfate in Wistar rat plasma and its application to pharmacokinetic study. Int J App Pharm. 2022;14(1):106-11. doi: 10.22159/ijap.2022v14i1.43328.

13. European Medicines Agency. Guideline on bioanalytical method validation science and medicinal health. European Medicines Agency (EMEA), EMEA, CHMP, EWP/192217; 2009.

14. Kiran GS, Cheruku S, Cheruku S, Bhikshapathi D, Palanati M. An LC–MS/MS quantification method development and validation for the dabrafenib in biological matrices. J Appl Pharm Sci. 2023;13(1):180-6. doi: 10.7324/JAPS.2023.130117.

15. Kaza M, Karazniewicz Lada M, Kosicka K, Siemiątkowska A, Rudzki PJ. Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse? J Pharm Biomed Anal. 2019;165:381-5. doi: 10.1016/j.jpba.2018.12.030, PMID 30590335.

16. Smith G. European medicines agency guideline on bioanalytical method validation: what more is there to say? Bioanalysis. 2012;4(8):865-8. doi: 10.4155/bio.12.44, PMID 22533559.

17. Ponnuri RN, Pragallapati P, NR, Mandava VB. A rapid and sensitive liquid chromatography mass spectrometry/mass spectrometry method for estimation of pioglitazone keto pioglitazone and hydroxy pioglitazone in human plasma. Asian J Pharm Clin Res. 2017;10(12):120-8. doi: 10.22159/ajpcr.2017.v10i12.20284.

18. Sura RS, CVS S, Rachamalla SS. Bioanalytical RP-HPLC method development and validation of clopidogrel bisulfate in Wistar rat plasma and its application to pharmacokinetic study. Int J App Pharm. 2022;14(1):106-11. doi: 10.22159/ijap.2022v14i1.43328.

19. Lolla S, Gubbiyappa KS, Cheruku S, Bhikshapathi DV. Validation of an LC-MS/MS method for quantitation of fostemsavir in plasma. J Pharmacol Toxicol Methods. 2023;120:107254. doi: 10.1016/j.vascn.2023.107254, PMID 36863666.

20. Nuli MV, Rekulapally VK. Overall review on analytical method development and validation of Dasatinib. Int J Pharm Chem. 2023;14(1):27-34. doi: 10.46796/ijpc.v4i1.432.

21. Sellappan M, Devakumar D. Development and validation of RP-HPLC method for the estimation of escitalopram oxalate and flupentixoldihydrochloride in combined dosage form and plasma. Int J Pharm Pharm Sci. 2021 Feb 1;13(2):61-6. doi: 10.22159/ijpps.2021v13i2.30158.

22. Dadhaniya T, Chaudhary K, Mehta P. Development of LC-MS/MS method for determination of iloperidone in rabbit plasma: application to a pharmacokinetic study. Int J Pharm Pharm Sci. 2013;7(4):294-7.

23. Puttagunta SB, Shaik RP, Bannoth CK, Challa BS, Awen BZ. Bioanalytical method for quantification of solifenacin in rat plasma by LC-MS/MS and its application to pharmacokinetic study. J Anal Sci Technol. 2014;5(1):35. doi: 10.1186/s40543-014-0035-0.

24. Kumar BA, Ramesh B, Cheruku S, Bhikshapathi DV. Method development validation and application of liquid chromatography electrospray ionization-mass spectrometry/mass spectrometry method for the quantification of amprenavir in plasma samples. J Appl Pharm Sci. 2022;12(07):115-21. doi: 10.7324/JAPS.2022.120712.

25. Christian S, Rashmikant Patel S. A rapid and sensitive LC-MS/MS assay for the determination of clobazam in human plasma using electrospray ionization technology. Int J Pharm Sci Res. 2018 Jun;9(6):2369-77. doi: 10.13040/IJPSR.0975-8232.9(6).2369-77.

26. Sellappan M, Devakumar D. Development and validation of RP-HPLC method for the estimation of escitalopram oxalate and flupentixoldihydrochloride in combined dosage form and plasma. Int J Pharm Pharm Sci. 2021 Feb 1;13(2):61-6. doi: 10.22159/ijpps.2021v13i2.30158.

27. Sellappan M, Devakumar D. Development and validation of RP-HPLC method for the estimation of escitalopram oxalate and flupentixoldihydrochloride in combined dosage form and plasma. Int J Pharm Pharm Sci. 2021 Feb 1;13(2):61-6. doi: 10.22159/ijpps.2021v13i2.30158.

28. Gurav P, Damle M. Bioanalytical method for estimation of teriflunomidein human plasma. Int J Pharm Pharm Sci. 2022 Sep 1;14(9):19-23. doi: 10.22159/ijpps.2022v14i9.45151.

29. Krishnan VS, Bhikshapathi D, Cheruku S. Method development and validation for the quantification of abametapir in biological matrices by LC-ESI-MS/MS. Ind J Pharm Edu Res. 2024;58(3s):s1028-33. doi: 10.5530/ijper.58.3s.102.